Clovis Oncology, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Clovis Oncology, Inc.
Harbinger Health CEO Stephen Hahn On Early Cancer Detection To ‘Move The Needle’ On Survival
Medtech Insight spoke with Stephen Hahn, ex-FDA commissioner and CEO of Harbinger Health, who attended SXSW, about the firm’s blood-based cancer test in development.
Finance Watch: Founder-Friendly Curie.Bio Launches With $520m To Seed, Support New Companies
Private Company Edition: Alexis Borisy and his Curie.Bio co-founders will invest $5m-$7m to help companies get to lead optimization within 12-18 months. Also, Feng Zhang-founded Aera launched with $193m, Hexagon Bio raised a $77.3m series B round and Halda emerged with $76m.
Can Lynparza Hold On As PARP Inhibitors Enter First-Line Prostate Cancer Market?
AstraZeneca, Pfizer and Johnson & Johnson are presenting Phase III data for PARP inhibitors combined with anti-androgen drugs in first-line mCRPC, a potential blockbuster opportunity.
Stock Watch: Post-Pandemic Drug Commercialization Shifts
Emerging from the pandemic after nearly three years, therapy areas and drug classes are traveling at different speeds.
- Specialty Pharmaceuticals
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Other Names / Subsidiaries
- Ethical Oncology Science S.p.A. (EOS S.p.A.)
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.